<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="880">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04649320</url>
  </required_header>
  <id_info>
    <org_study_id>1264/2020</org_study_id>
    <nct_id>NCT04649320</nct_id>
  </id_info>
  <brief_title>Perception of the COVID-19 Pandemic in Patients With Haematological or Solid Neoplasias</brief_title>
  <official_title>Investigation of the Perception of the COVID-19 Pandemic in Patients With Haematological or Solid Neoplasias Using Patient-reported Outcome Measures (PROMs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University Innsbruck</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cancer patients are among the most vulnerable individuals, whose health-related quality of&#xD;
      life (HRQOL) may be substantially impacted by the COVID19 pandemic. We want to study how the&#xD;
      COVID-19 pandemic influences the life of cancer patients and how these patients cope with the&#xD;
      additional distress with the aim to facilitate the development of improved future&#xD;
      interventional strategies to maintain resilience and HRQOL&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In December 2019, the novel human pathogenic virus &quot;SARS-CoV2&quot; from the coronavirus family&#xD;
      was identified, causing a respiratory disease known as &quot;COVID19&quot; (coronavirus disease 2019).&#xD;
      COVID19 manifests itself primarily with influenza-like symptoms, but in special cases it can&#xD;
      lead to severe conditions such as ARDS (acute respiratory distress syndrome). Compared to&#xD;
      other pulmotropic viruses such as the influenza virus, SARS-CoV-2 is associated with a higher&#xD;
      contagiousness and mortality.&#xD;
&#xD;
      Haematological and oncological patients are particularly vulnerable due to their advanced&#xD;
      age, immunological restrictions in the context of the underlying disease and the treatment&#xD;
      modalities (chemotherapy, radiation therapy, ...).&#xD;
&#xD;
      To evaluate the effects of the COVID19 pandemic on the perception of patients with malignant&#xD;
      diseases, we aim to record so-called &quot;patient-reported outcomes&quot; (PROs) from patients at the&#xD;
      University Hospital of Innsbruck at the Department of Internal Medicine V (Hematology and&#xD;
      Oncology) and at the Department for Radiotherapy and Radiation Oncology. We use the validated&#xD;
      EORT QLQ-C30 and a specially developed questionnaire for COVID19.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 23, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Influence of the COVID-19 pandemic on cancer patient's daily life</measure>
    <time_frame>single time</time_frame>
    <description>evaluation via questionnaire</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>cancer patients</arm_group_label>
    <description>adult cancer patients, with solid or hematologic malignancies, neither tested positive nor having COVID19 symptoms</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire</intervention_name>
    <description>13-item questionnaire about cancer patient's distress and everyday life,&#xD;
EORTC-QLQ-C30</description>
    <arm_group_label>cancer patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        adult cancer patients, with solid or hematologic malignancies, neither tested positive nor&#xD;
        having COVID19 symptoms, with an age over 18 years&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  validated hematological or oncological disease&#xD;
&#xD;
          -  informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Insufficient discernment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reinhard Stauder, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Innsbruck, Anichstra√üe 35, A-6020 Innsbruck, Austria</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reinhard Stauder, M.D.</last_name>
    <phone>+43 512 504 81387</phone>
    <email>reinhard.stauder@i-med.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <state>Tyrol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reinhard Stauder, M.D.</last_name>
      <phone>+43 512 504 81387</phone>
      <email>reinhard.stauder@i-med.ac.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>November 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2020</study_first_posted>
  <last_update_submitted>November 30, 2020</last_update_submitted>
  <last_update_submitted_qc>November 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>COVID19 pandemic</keyword>
  <keyword>cancer patients</keyword>
  <keyword>distress</keyword>
  <keyword>HRQOL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

